MA35061B1 - Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase - Google Patents

Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase

Info

Publication number
MA35061B1
MA35061B1 MA36357A MA36357A MA35061B1 MA 35061 B1 MA35061 B1 MA 35061B1 MA 36357 A MA36357 A MA 36357A MA 36357 A MA36357 A MA 36357A MA 35061 B1 MA35061 B1 MA 35061B1
Authority
MA
Morocco
Prior art keywords
acetyl
coa carboxylase
pyrazolospirocetone
derivatives
carboxylase inhibitors
Prior art date
Application number
MA36357A
Other languages
English (en)
Inventor
David Andrew Griffith
Robert Lee Dow
James Alfred Southers Jr
David James Edmonds
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA35061B1 publication Critical patent/MA35061B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Photographic Processing Devices Using Wet Methods (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'INVENTION PORTE SUR UN COMPOSÉ DE FORMULE (I) OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, DANS LAQUELLE FORMULE G REPRÉSENTE (II) OU (III) ET R1, R2 ET R3 SONT TELS QUE DÉCRITS DANS LA DESCRIPTION ; SUR DES COMPOSITIONS PHARMACEUTIQUES DE CELUI-CI ; ET SUR LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES, D'AFFECTIONS OU DE TROUBLES MODULÉS PAR L'INHIBITION D'UNE OU PLUSIEURS ENZYMES ACÉTYL-COA CARBOXYLASES CHEZ UN ANIMAL.
MA36357A 2011-04-22 2012-04-09 Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase MA35061B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478240P 2011-04-22 2011-04-22
PCT/IB2012/051732 WO2012143813A1 (fr) 2011-04-22 2012-04-09 Dérivés de pyrazolospirocétone destinés à être utilisés comme inhibiteurs d'acétyl-coa carboxylase

Publications (1)

Publication Number Publication Date
MA35061B1 true MA35061B1 (fr) 2014-04-03

Family

ID=46025823

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36357A MA35061B1 (fr) 2011-04-22 2012-04-09 Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase

Country Status (43)

Country Link
US (4) US8802688B2 (fr)
EP (1) EP2699576B1 (fr)
JP (1) JP5657174B2 (fr)
KR (1) KR101567659B1 (fr)
CN (2) CN106117205B (fr)
AP (1) AP3499A (fr)
AR (1) AR086198A1 (fr)
AU (1) AU2012245996B2 (fr)
CA (1) CA2831380C (fr)
CL (1) CL2013002794A1 (fr)
CO (1) CO6801757A2 (fr)
CR (1) CR20130464A (fr)
CU (1) CU24164B1 (fr)
CY (1) CY1117122T1 (fr)
DK (1) DK2699576T3 (fr)
DO (1) DOP2013000243A (fr)
EA (1) EA022375B1 (fr)
EC (1) ECSP13013038A (fr)
ES (1) ES2561452T3 (fr)
GE (1) GEP20166474B (fr)
GT (1) GT201300258A (fr)
HR (1) HRP20151397T1 (fr)
HU (1) HUE028602T2 (fr)
IL (1) IL228949A (fr)
MA (1) MA35061B1 (fr)
ME (1) ME02312B (fr)
MX (1) MX348860B (fr)
MY (1) MY162167A (fr)
NI (1) NI201300111A (fr)
NZ (1) NZ616156A (fr)
PE (1) PE20141187A1 (fr)
PH (1) PH12013501941A1 (fr)
PL (1) PL2699576T3 (fr)
PT (1) PT2699576E (fr)
PY (1) PY1218709A (fr)
RS (1) RS54526B1 (fr)
SG (1) SG194142A1 (fr)
SI (1) SI2699576T1 (fr)
TN (1) TN2013000393A1 (fr)
TW (1) TWI464171B (fr)
UA (1) UA107753C2 (fr)
UY (1) UY34027A (fr)
WO (1) WO2012143813A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2947082A1 (fr) * 2009-11-10 2015-11-25 Pfizer Inc INHIBITEURS DE N1-PYRAZOLOSPIROCÉTONE ACÉTYL-CoA CARBOXYLASE
CN102491974B (zh) * 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
US9447026B2 (en) 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
EP2994139B1 (fr) 2013-05-10 2019-04-10 Gilead Apollo, LLC Inhibiteurs de l'acc et leurs utilisations
AU2014262547A1 (en) 2013-05-10 2015-11-26 Gilead Apollo, Llc ACC inhibitors and uses thereof
JP6417401B2 (ja) * 2013-05-10 2018-11-07 ギリアド アポロ， エルエルシー Ａｃｃ阻害剤及びその使用
US20160220557A1 (en) * 2013-09-12 2016-08-04 Pfizer Inc. Use of acetyl-coa carboxylase inhibitors for treating acne vulgaris
EP3670496A3 (fr) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Inhibiteurs de acc2
CA2932039A1 (fr) * 2013-12-12 2015-06-18 Kalyra Pharmaceuticals, Inc. Composes d'alkyle bicyclique et synthese
CN113336653A (zh) 2014-03-07 2021-09-03 里科瑞尔姆Ip控股有限责任公司 螺桨烷衍生物及合成
CA2892342C (fr) 2014-05-22 2016-11-01 Sylvain-Paul Morency Outil et methode de depalletisation de couche
US10308609B2 (en) 2014-09-17 2019-06-04 Zeno Royalties & Milestones, LLC Bicyclic compounds
AU2016383376B2 (en) * 2015-12-31 2022-07-28 Beijing Gushen Life Health Technology Co., Ltd. Triacetyl-3-hydroxyphenyladenosine and application in preparing pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
US11242327B2 (en) 2017-05-15 2022-02-08 Recurium Ip Holdings, Llc Analgesic compounds
CN111406056B (zh) 2017-11-21 2023-02-28 辉瑞公司 选择性acc抑制剂的结晶2-氨基-2-(羟甲基)丙烷-1,3-二醇盐
LT3796975T (lt) 2018-05-22 2023-12-11 Orsobio, Inc. Sulfonilaminobenzamido dariniai
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途
CN120457124A (zh) * 2022-12-30 2025-08-08 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
CN121241054A (zh) * 2023-04-14 2025-12-30 北京双鹤润创科技有限公司 氮杂环羰基稠环衍生物及其用途
CN121909191A (zh) * 2023-08-16 2026-04-21 智擎生技制药股份有限公司 Mta协同性的prmt5抑制剂

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
CA2439152C (fr) 2001-02-28 2008-06-17 Merck & Co., Inc. Derives de piperidine acylee tels que les agonistes du recepteur 4 de la melanocortine
CN1642599A (zh) 2002-02-27 2005-07-20 辉瑞产品公司 Acc抑制剂
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (fr) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. Derive spiro, procede de production et antioxydant
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
PL1753748T3 (pl) 2004-05-12 2010-01-29 Pfizer Prod Inc Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV
WO2005113069A2 (fr) 2004-05-14 2005-12-01 Research Development Foundation Utilisation de curcumine et d'analogues de curcumine comme inhibiteurs de l'acc2
AP2006003768A0 (en) 2004-05-25 2006-10-31 Pfizer Prod Inc TetraazabenzoÄeÜazulene derivatives and analogs tehereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
WO2007011809A1 (fr) 2005-07-19 2007-01-25 Merck & Co., Inc. Derives de spirochromanone utilises en tant quinhibiteurs d'acetyle coenzyme a carboxylase
CA2617042A1 (fr) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Compose spiro-cyclique
JP2009515971A (ja) 2005-11-18 2009-04-16 メルク エンド カムパニー インコーポレーテッド スピロヒダントインアリールｃｇｒｐ受容体アンタゴニスト
JP2009526868A (ja) 2006-02-15 2009-07-23 アボット・ラボラトリーズ 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
EP2010520B1 (fr) 2006-04-20 2012-09-12 Pfizer Products Inc. Amides hétérobicycliques pour la prévention et le traitement de maladies à médiation par glucokinase
BRPI0721053A2 (pt) 2006-11-29 2014-07-29 Pfizer Prod Inc INIBIDORES DE ESPIROCETONA ACETIL-CoA CARBOXILASE
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
JPWO2008102749A1 (ja) * 2007-02-20 2010-05-27 武田薬品工業株式会社 複素環化合物
AU2008237660B2 (en) 2007-04-12 2011-12-22 Pfizer Inc. 3-amido-pyrrolo [3, 4-C] pyrazole-5 (1H, 4H, 6H) carbaldehyde derivatives as inhibitors of protein kinase C
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
WO2009144555A1 (fr) 2008-05-28 2009-12-03 Pfizer Inc. Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase
JP5435592B2 (ja) * 2008-05-28 2014-03-05 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
WO2010002010A1 (fr) * 2008-07-04 2010-01-07 Banyu Pharmaceutical Co.,Ltd. Nouveaux acides spirochromanone carboxyliques
AU2009271634A1 (en) 2008-07-14 2010-01-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
JP2011529483A (ja) 2008-07-29 2011-12-08 ファイザー・インク フッ素化ヘテロアリール
AU2009286380B2 (en) 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
EP2604604A1 (fr) 2009-03-11 2013-06-19 Pfizer Inc Dérivés de benzofuranyle utilisés comme inhibiteurs de la glucokinase
CA2754685A1 (fr) 2009-03-11 2010-09-16 Pfizer Inc. Indazole amides substitues
WO2010106457A2 (fr) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3,3.1]nonanes
US20120052130A1 (en) 2009-05-08 2012-03-01 Pfizer Inc. Gpr 119 modulators
CA2759843A1 (fr) 2009-05-08 2010-11-10 Pfizer Inc. Modulateurs de gpr119
NZ596467A (en) 2009-06-05 2014-01-31 Pfizer L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (fr) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Agonistes du récepteur de la neuromédine u et leurs utilisations
EP2499140A1 (fr) * 2009-11-10 2012-09-19 Pfizer Inc. Inhibiteurs de n2-pyrazolospirocétone acétyl-coa carboxylase
EP2947082A1 (fr) * 2009-11-10 2015-11-25 Pfizer Inc INHIBITEURS DE N1-PYRAZOLOSPIROCÉTONE ACÉTYL-CoA CARBOXYLASE
HRP20161178T1 (hr) * 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE

Also Published As

Publication number Publication date
AR086198A1 (es) 2013-11-27
EA201391288A1 (ru) 2014-04-30
PL2699576T3 (pl) 2016-05-31
TW201305162A (zh) 2013-02-01
PT2699576E (pt) 2016-03-09
CN103492388A (zh) 2014-01-01
DOP2013000243A (es) 2013-12-31
CN106117205A (zh) 2016-11-16
CA2831380C (fr) 2016-04-05
MX2013012313A (es) 2014-01-31
CO6801757A2 (es) 2013-11-29
TN2013000393A1 (fr) 2015-01-20
US8802688B2 (en) 2014-08-12
CL2013002794A1 (es) 2013-12-27
CU20130126A7 (es) 2014-01-29
AP2013007129A0 (en) 2013-09-30
AU2012245996A1 (en) 2013-10-03
KR101567659B1 (ko) 2015-11-09
US20120270893A1 (en) 2012-10-25
NZ616156A (en) 2014-08-29
MX348860B (es) 2017-06-30
SG194142A1 (en) 2013-11-29
US20150112068A1 (en) 2015-04-23
HUE028602T2 (hu) 2016-12-28
EP2699576A1 (fr) 2014-02-26
EA022375B1 (ru) 2015-12-30
CY1117122T1 (el) 2017-04-05
AP3499A (en) 2015-12-31
PE20141187A1 (es) 2014-09-18
PH12013501941A1 (en) 2021-06-23
CU24164B1 (es) 2016-03-31
UA107753C2 (xx) 2015-02-10
PY1218709A (es) 2016-01-01
US20150336958A1 (en) 2015-11-26
AU2012245996B2 (en) 2016-09-01
DK2699576T3 (en) 2016-02-15
UY34027A (es) 2013-04-05
JP5657174B2 (ja) 2015-01-21
ES2561452T3 (es) 2016-02-26
HRP20151397T1 (hr) 2016-01-15
MY162167A (en) 2017-05-31
SI2699576T1 (sl) 2016-02-29
GEP20166474B (en) 2016-05-10
NI201300111A (es) 2014-02-12
US20140323730A1 (en) 2014-10-30
GT201300258A (es) 2015-06-02
WO2012143813A1 (fr) 2012-10-26
IL228949A0 (en) 2013-12-31
EP2699576B1 (fr) 2015-12-09
RS54526B1 (sr) 2016-06-30
KR20140015511A (ko) 2014-02-06
TWI464171B (zh) 2014-12-11
JP2014515755A (ja) 2014-07-03
CN106117205B (zh) 2018-09-21
ECSP13013038A (es) 2014-01-31
ME02312B (me) 2016-06-20
CA2831380A1 (fr) 2012-10-26
IL228949A (en) 2016-11-30
CR20130464A (es) 2013-10-16

Similar Documents

Publication Publication Date Title
MA35061B1 (fr) Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MA38461A1 (fr) Inhibiteurs de la voie de la kynurénine
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
MA55046B1 (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MA38333A1 (fr) Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA33760B1 (fr) Dérivés spirolactames et leurs utilisations
MA46342A (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
EA201170150A1 (ru) Применение производных индола в качестве активаторов nurr-1 при лечении болезни паркинсона
MA33619B1 (fr) Agent thérapeutique pour des troubles de l'anxiété